Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomohide Tamura

Showing results (51-60 of 263) with videos related to

Pageof 27
Sort By:
Breast Cancer Research : BCR|June 23, 2011
Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3Yasuo Kodera, Yasufumi Katanasaka, Yuka Kitamura, et al.
Cancer Chemotherapy and Pharmacology|August 3, 2010
Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumorsYutaka Ueda, Tatsu Shimoyama, Haruyasu Murakami, et al.
Cancer Treatment Reviews|May 18, 2004
Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trialsIkuo Sekine, Noboru Yamamoto, Hideo Kunitoh, et al.
Cancer Science|September 26, 2012
Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancerHidehito Horinouchi, Ikuo Sekine, Minako Sumi, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2006
Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancerIkuo Sekine, Hiroshi Nokihara, Noboru Yamamoto, et al.
Cancer Chemotherapy and Pharmacology|May 8, 2007
Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumorsNoboru Yamamoto, Atsushi Horiike, Yasuhito Fujisaka, et al.
Future Oncology (London, England)|June 9, 2016
Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two Phase II studiesShinji Atagi, Koichi Goto, Takashi Seto, et al.
Cancer Science|July 11, 2006
High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patientsHideharu Kimura, Yutaka Fujiwara, Takashi Sone, et al.
Clinical Lung Cancer|September 6, 2011
Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancerHajime Asahina, Ikuo Sekine, Hidehito Horinouchi, et al.
Respiratory Investigation|January 9, 2022
Bronchoscopy for the diagnosis of nontuberculous mycobacterial pulmonary disease: Specificity and diagnostic yield in a retrospective cohort studyYutaka Tomishima, Kevin Y Urayama, Atsushi Kitamura, et al.
Pageof 27

Showing results (51-60 of 263) with videos related to

Sort By:
Pageof 27
Breast Cancer Research : BCR|June 23, 2011
Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3Yasuo Kodera, Yasufumi Katanasaka, Yuka Kitamura, et al.
Cancer Chemotherapy and Pharmacology|August 3, 2010
Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumorsYutaka Ueda, Tatsu Shimoyama, Haruyasu Murakami, et al.
Cancer Treatment Reviews|May 18, 2004
Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trialsIkuo Sekine, Noboru Yamamoto, Hideo Kunitoh, et al.
Cancer Science|September 26, 2012
Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancerHidehito Horinouchi, Ikuo Sekine, Minako Sumi, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2006
Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancerIkuo Sekine, Hiroshi Nokihara, Noboru Yamamoto, et al.
Cancer Chemotherapy and Pharmacology|May 8, 2007
Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumorsNoboru Yamamoto, Atsushi Horiike, Yasuhito Fujisaka, et al.
Future Oncology (London, England)|June 9, 2016
Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two Phase II studiesShinji Atagi, Koichi Goto, Takashi Seto, et al.
Cancer Science|July 11, 2006
High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patientsHideharu Kimura, Yutaka Fujiwara, Takashi Sone, et al.
Clinical Lung Cancer|September 6, 2011
Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancerHajime Asahina, Ikuo Sekine, Hidehito Horinouchi, et al.
Respiratory Investigation|January 9, 2022
Bronchoscopy for the diagnosis of nontuberculous mycobacterial pulmonary disease: Specificity and diagnostic yield in a retrospective cohort studyYutaka Tomishima, Kevin Y Urayama, Atsushi Kitamura, et al.
Pageof 27